A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about the health and the diabetes treatment. Participants will complete these during the normally scheduled visits with the study doctor.

Official Title
-----------------
SURE CANADA: A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once Weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: Semaglutide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study Male or female, age greater than or equal to 18 years at the time of signing informed consent Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion Available and documented HbA1c value less than or equal to 12 weeks prior to initiation of semaglutide treatment Exclusion Criteria: Previous participation in this study. Participation is defined as having given informed consent in this study Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation Treatment with any investigational drug within 90 days prior to enrolment into the study Hypersensitivity to semaglutide or to any of the excipients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Semaglutide<br>Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks | Drug: Semaglutide<br>* Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Glycated Haemoglobin A1c (HbA1c) | Measured in % points | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38) | 
| Change in HbA1c | Measured in mmol/mol | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in body weight | Measured in kg | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38) | 
| Change in body weight | Measured in % | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38) | 
| Change in waist circumference | Measured in cm | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38) | 
| HbA1c level at end of study: < 8.0% (64 mmol/mol) (yes/no) | Number of participants who achieved/not achieved HbA1c level at end of study: <8.0% | At end of study (week 28-38) | 
| HbA1c level at end of study: <7.5% (59 mmol/mol) (yes/no) | Number of participants who achieved/not achieved HbA1c level at end of study: <7.5% | At end of study (week 28-38) | 
| HbA1c level at end of study: <7.0% (53 mmol/mol) (yes/no) | Number of participants who achieved/not achieved HbA1c level at end of study: <7.0% | At end of study (week 28-38) | 
| Reduction in HbA1c of 1.0% point or more (yes/no) | Number of participants who achieved/not achieved reduction in HbA1c of 1.0% point or more | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38) | 
| Weight reduction of 3.0% or more (yes/no) | Number of participants who achieved/not achieved weight reduction of 3.0% or more | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38) | 
| Weight reduction of 5.0% or more (yes/no) | Number of participants who achieved/not achieved weight reduction of 5.0% or more | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38) | 
| HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no) | Number of participants who achieved/not achieved HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38) | 
| Patient reported severe or documented hypoglycaemia (yes/no) | Number of participants who reported/not reported severe or documented hypogycaemia | Between baseline (week 0) and end of study (week 28-38) | 
| Change in Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction | The status version (DTSQs) provides a measure of how satisfied patients are with their current diabetes treatment. It consists of 8 questions, which are to be answered on a Likert scale from 0 to 6 (0 = very dissatisfied to 6 = very satisfied). Six questions are summed to produce a total Treatment Satisfaction score. The remaining two questions are concerning perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia, respectively. | Baseline (week 0), end of study (week 28-38) | 
| Change in Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction | The change version (DTSQc) has the same 8 items as the status version, but is reworded to direct the patients to compare the experience of the current treatment with the experience of previous treatment. Each question is scored on a scale of -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change. | Baseline (week 0), end of study (week 28-38) | 
| Change in Short Form (SF)-36 v2: Physical summary component | The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health). | Baseline (week 0), end of study (week 28-38) | 
| Change in SF-36 v2: Mental summary component | The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health). | Baseline (week 0), end of study (week 28-38) | 
| Patient completed the study under treatment with semaglutide (yes/no) | Number of patients who completed/not completed the study under treatment with semaglutide | At end of study (week 28-38) |